AKT1 and neoplasm: A modulation of PD biomarkers in terms of downregulation of EGFR, AKT and CDK4 client proteins was achieved either in vitro, on A431 tumor cells treated with SST0116CL1, and in terms of down-modulation of c-Met, AKT and CDK4 ex vivo in tumor lesions collected from GTL-16 tumor-bearing mice.